These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://ammardcam189657.bloggerbags.com/44719247/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide